[go: up one dir, main page]

MA28032A1 - Utilisation de cyclosporines modifiees pour le traitement de troubles lies au vhc - Google Patents

Utilisation de cyclosporines modifiees pour le traitement de troubles lies au vhc

Info

Publication number
MA28032A1
MA28032A1 MA28865A MA28865A MA28032A1 MA 28032 A1 MA28032 A1 MA 28032A1 MA 28865 A MA28865 A MA 28865A MA 28865 A MA28865 A MA 28865A MA 28032 A1 MA28032 A1 MA 28032A1
Authority
MA
Morocco
Prior art keywords
treatment
related disorders
cyclosporins
hcv related
modified cyclosporins
Prior art date
Application number
MA28865A
Other languages
English (en)
Inventor
Makoto Hijikata
Kunitada Shimotohno
Koichi Watashi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA28032A1 publication Critical patent/MA28032A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cette invention concerne ses cyclosporines sans activité immunosuppressive se liant à la cyclophiline (voir formules I, Ia ou II) comme définies dans le descriptif, qui possèdent des propriétés puissantes dans la prévention ou le traitement des infections par le virus de l'hépatite C.
MA28865A 2003-09-03 2006-03-10 Utilisation de cyclosporines modifiees pour le traitement de troubles lies au vhc MA28032A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0320638.0A GB0320638D0 (en) 2003-09-03 2003-09-03 Organic compounds

Publications (1)

Publication Number Publication Date
MA28032A1 true MA28032A1 (fr) 2006-07-03

Family

ID=28686843

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28865A MA28032A1 (fr) 2003-09-03 2006-03-10 Utilisation de cyclosporines modifiees pour le traitement de troubles lies au vhc

Country Status (29)

Country Link
US (1) US7968518B2 (fr)
EP (2) EP1663287B1 (fr)
JP (1) JP4688806B2 (fr)
KR (1) KR101116968B1 (fr)
CN (1) CN1842343A (fr)
AU (2) AU2004268382A1 (fr)
BR (1) BRPI0414062B8 (fr)
CA (1) CA2537137C (fr)
CY (1) CY1110506T1 (fr)
DE (1) DE602004022061D1 (fr)
DK (1) DK1663287T3 (fr)
ES (1) ES2328361T3 (fr)
GB (1) GB0320638D0 (fr)
HR (1) HRP20090535T1 (fr)
IL (1) IL173909A (fr)
IS (1) IS2917B (fr)
MA (1) MA28032A1 (fr)
MX (1) MXPA06002394A (fr)
NO (1) NO20061479L (fr)
NZ (1) NZ545495A (fr)
PL (1) PL1663287T3 (fr)
PT (1) PT1663287E (fr)
RU (1) RU2389501C2 (fr)
SG (1) SG149063A1 (fr)
SI (1) SI1663287T1 (fr)
TN (1) TNSN06071A1 (fr)
TW (1) TWI342782B (fr)
WO (1) WO2005021028A1 (fr)
ZA (1) ZA200601550B (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2255275T3 (es) 1998-07-01 2006-06-16 Debiopharm S.A. Nueva ciclosporina con perfil de actividad mejorado.
CA2518265A1 (fr) 2003-03-17 2004-09-30 Albany Molecular Research, Inc. Nouvelles cyclosporines
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
GB0500020D0 (en) * 2005-01-04 2005-02-09 Novartis Ag Organic compounds
BRPI0513370A (pt) 2004-07-14 2008-05-06 Novartis Ag uso de uma combinação de ciclosporina e interferonas peguilados para tratamento de hepatite c (hcv)
US7511013B2 (en) 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
JP2008514701A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド シクロスポリンアルキン類似体およびそれらの薬学的使用
EP1802650B1 (fr) * 2004-10-01 2011-10-26 Scynexis, Inc. Derives de cyclosporine 3-ether et 3-thioether substitues utilises dans le traitement et la prevention d'une infection par hepatite c
EP1793844B1 (fr) * 2004-10-01 2010-12-08 Debiopharm S.A. Utilisation de cyclosporine dans le traitement d'infections a hepatite c
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
WO2006041631A2 (fr) 2004-10-06 2006-04-20 Amr Technology, Inc. Alcynes de cyclosporine, et leur utilite comme agents pharmaceutiques
DE602005010607D1 (de) 2004-11-22 2008-12-04 Astellas Pharma Inc Zyklosporinanalog
AU2005322242B2 (en) * 2004-12-23 2010-02-11 Novartis Ag Compositions for HCV treatment
JP2008525458A (ja) * 2004-12-23 2008-07-17 ノバルティス アクチエンゲゼルシャフト フラビウイルス科処置用化合物
AR054778A1 (es) 2005-06-17 2007-07-18 Novartis Ag Uso de sangliferina en hcv
BRPI0616476A2 (pt) * 2005-09-30 2011-06-21 Scynexis Inc uso de uma quantidade terapeuticamente eficaz de um derivado de ciclosporina, e, composição farmacêutica
CN101316606B (zh) * 2005-09-30 2015-05-27 西尼克斯公司 治疗和预防丙型肝炎感染的方法和药物组合物
WO2007041631A1 (fr) * 2005-09-30 2007-04-12 Scynexis, Inc. Derives d'arylalkyle et d'heteroarylalkyle de cyclosporine a utilises pour traiter et prevenir une infection virale
PT1957518E (pt) * 2005-10-26 2016-02-26 Astellas Pharma Inc Novos compostos peptídicos cíclicos
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US8188052B2 (en) 2006-05-19 2012-05-29 Scynexis, Inc. Method for the treatment and prevention of ocular disorders
WO2007141395A1 (fr) * 2006-06-02 2007-12-13 Claude Annie Perrichon Gestion des electrons actifs
BRPI0719189A2 (pt) * 2006-10-12 2018-08-14 Univ Kyushu Nat Univ Corp uso de ciclosporinas modificadas
WO2008069917A2 (fr) * 2006-11-20 2008-06-12 Scynexis, Inc. Nouveaux peptides cycliques
AU2008204344B2 (en) * 2007-01-04 2013-01-31 Debiopharm Sa Non-immunosuppressive cyclosporin for treatment of Ullrich congenital muscular dystrophy
JP5459545B2 (ja) 2007-05-02 2014-04-02 アステラス製薬株式会社 新規環状ペプチド化合物
US20110158908A1 (en) * 2007-08-24 2011-06-30 Sapporo Medical University Cyclosporin a-binding protein
CN102083852A (zh) * 2008-06-06 2011-06-01 西尼克斯公司 环孢菌素类似物及其在治疗hcv感染中的应用
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
NZ590517A (en) * 2008-07-30 2012-12-21 Isotechnika Pharma Inc Nonimmunosuppressive cyclosporine analogue molecules
WO2010035722A1 (fr) * 2008-09-24 2010-04-01 アステラス製薬株式会社 Composé peptidique et son procédé de production
MX2011004881A (es) * 2008-11-06 2011-08-12 Debio Rech Pharma Sa Compuestos cicloundecadepsipeptidos y el uso de dichos compuestos como un medicamento.
JP5780969B2 (ja) * 2008-12-31 2015-09-16 サイネクシス，インコーポレーテッド シクロスポリンａの誘導体
EP2391376A4 (fr) * 2009-01-30 2012-08-01 Enanta Pharm Inc Analogues de la cyclosporine pour prévenir ou traiter une infection par l'hépatite c
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US20110117055A1 (en) 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
CN102869367A (zh) 2009-12-09 2013-01-09 西尼克斯公司 新颖的环肽
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
CN103179974A (zh) 2010-10-05 2013-06-26 诺华有限公司 丙型肝炎病毒感染的新疗法
EP2646038A1 (fr) 2010-11-30 2013-10-09 Novartis AG Nouveaux traitements de l'infection par le virus de l'hépatite c
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
CN107496902B (zh) 2010-12-15 2022-01-18 康卓维尔制药公司 在氨基酸1和3位修改的环孢菌素类似分子
CA2831428A1 (fr) 2011-03-31 2012-10-04 Novartis Ag Alisporivir pour le traitement d'une infection par le virus de l'hepatite c
BR112013024809A2 (pt) 2011-04-01 2016-09-06 Novartis Ag tratamento para infecção com vírus de hepatite b sozinho ou em combinação com vírus de hepatite delta e doenças do fígado associadas
SG10201602184TA (en) 2011-04-13 2016-04-28 Novartis Ag Treatment of hepatitis c virus infection with alisporivir
CN103826654A (zh) 2011-09-27 2014-05-28 诺华股份有限公司 用于治疗丙型肝炎病毒感染的阿拉泊韦
AU2013259841A1 (en) 2012-05-07 2014-10-30 Novartis Ag Pharmacokinetic modulation with alisporivir
US9266927B2 (en) 2012-06-01 2016-02-23 Allergan, Inc. Cyclosporin A analogs
US8906853B2 (en) 2012-11-28 2014-12-09 Enanta Pharmaceuticals, Inc. [N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection
WO2015008223A1 (fr) 2013-07-17 2015-01-22 Novartis Ag Traitement du virus de l'hépatite c avec l'alisporivir et la ribavirine
MX2016002458A (es) 2013-08-26 2016-08-08 Enanta Pharm Inc Análogos novedosos de ciclosporina para prevenir o tratar la infección por hepatitis c.
WO2015136455A1 (fr) 2014-03-13 2015-09-17 Novartis Ag Nouveaux traitements d'une infection par le virus de l'hépatite c
US9669095B2 (en) 2014-11-03 2017-06-06 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
WO2016112321A1 (fr) 2015-01-08 2016-07-14 Allergan, Inc. Dérivés de cyclosporine dans lesquels la chaîne latérale mebmt a été cyclisée
MX2023002109A (es) * 2020-08-24 2023-07-13 Nanomerics Ltd Inhibidores virales.

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
GB2222770B (en) 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
ATE148469T1 (de) * 1990-11-02 1997-02-15 Sandoz Ag Zyklosporine
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US6174868B1 (en) * 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
DE122011100012I1 (de) 1992-10-21 2011-10-20 Mitsubishi Tanabe Pharma Corp 2-Amino-1, 3-propandiolverbindung und immunosuppressium.
PT730470E (pt) 1993-11-10 2002-08-30 Enzon Inc Conjugados melhorados de interferao-polimero
WO1996006068A1 (fr) 1994-08-22 1996-02-29 Yoshitomi Pharmaceutical Industries, Ltd. Compose benzenique et son utilisation medicale
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP3786447B2 (ja) * 1995-03-31 2006-06-14 エーザイ株式会社 Ｃ型肝炎の予防・治療剤
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
FR2757521B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
FR2757522B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
IL155065A (en) 1997-04-04 2004-01-04 Mitsubishi Pharma Corp History - 2 Aminopropene - 1, 3 - Diol and Pharmaceutical Preparations Containing Them
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
ES2255275T3 (es) 1998-07-01 2006-06-16 Debiopharm S.A. Nueva ciclosporina con perfil de actividad mejorado.
CN1267429C (zh) 2000-07-13 2006-08-02 三共株式会社 氨基醇衍生物
CA2421893A1 (fr) 2000-08-31 2002-03-07 Merck And Co., Inc. Derives de phosphates utilises en tant qu'agents immuno-regulateurs
CA2426381A1 (fr) * 2000-10-19 2002-04-25 Fujisawa Pharmaceutical Co., Ltd. Inhibiteur de degat cellulaire
JP2002125683A (ja) * 2000-10-27 2002-05-08 Tokyoto Igaku Kenkyu Kiko インターフェロンの有効性を予測する方法並びにそれに用いられるプライマー及びプローブ
EP1377593B1 (fr) 2001-03-26 2005-12-28 Novartis AG Derives de 2-amino-propanol
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
CA2461212C (fr) 2001-09-27 2010-08-17 Kyorin Pharmaceutical Co., Ltd. Derive de sulfure de diaryle, sels correspondant et agents immunosuppresseur utilisant ces derives
US6963012B2 (en) 2001-09-27 2005-11-08 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
DE60330047D1 (en) 2002-01-18 2009-12-24 Merck & Co Inc "n-(benzyl)aminoalkyl carboxylate, phosphinate, phosphonate und tetrazole als edg rezeptoragonisten"
WO2003062252A1 (fr) 2002-01-18 2003-07-31 Merck & Co., Inc. Agonistes du recepteur edg
US20030213603A1 (en) 2002-05-14 2003-11-20 Fisher David B. Dual use extension apparatus for a tool
AU2003248748A1 (en) 2002-06-28 2004-01-19 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
GB0313444D0 (en) 2003-06-11 2003-07-16 Midland Medical Technologies L Modular dysplasia cup
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
EP1793844B1 (fr) 2004-10-01 2010-12-08 Debiopharm S.A. Utilisation de cyclosporine dans le traitement d'infections a hepatite c
AU2005322242B2 (en) 2004-12-23 2010-02-11 Novartis Ag Compositions for HCV treatment

Also Published As

Publication number Publication date
TW200524626A (en) 2005-08-01
HK1091732A1 (en) 2007-01-26
HRP20090535T1 (hr) 2009-11-30
US7968518B2 (en) 2011-06-28
IS8371A (is) 2006-03-24
GB0320638D0 (en) 2003-10-01
BRPI0414062A (pt) 2006-10-24
EP1663287B1 (fr) 2009-07-15
PT1663287E (pt) 2009-09-03
RU2006110533A (ru) 2007-10-10
NO20061479L (no) 2006-06-02
EP1797892A1 (fr) 2007-06-20
IS2917B (is) 2014-12-15
TNSN06071A1 (en) 2007-10-03
AU2004268382A1 (en) 2005-03-10
AU2008203031B2 (en) 2011-04-07
IL173909A (en) 2011-03-31
JP2007504260A (ja) 2007-03-01
EP1663287A1 (fr) 2006-06-07
SG149063A1 (en) 2009-01-29
PL1663287T3 (pl) 2009-12-31
MXPA06002394A (es) 2006-06-20
KR20060132798A (ko) 2006-12-22
CN1842343A (zh) 2006-10-04
CA2537137C (fr) 2013-05-28
BRPI0414062B8 (pt) 2021-05-25
SI1663287T1 (sl) 2009-10-31
JP4688806B2 (ja) 2011-05-25
IL173909A0 (en) 2006-07-05
RU2389501C2 (ru) 2010-05-20
WO2005021028A1 (fr) 2005-03-10
AU2008203031A1 (en) 2008-07-31
EP1797892B1 (fr) 2013-10-23
KR101116968B1 (ko) 2012-03-14
DE602004022061D1 (de) 2009-08-27
CA2537137A1 (fr) 2005-03-10
US20070275884A1 (en) 2007-11-29
NZ545495A (en) 2010-01-29
CY1110506T1 (el) 2015-04-29
ES2328361T3 (es) 2009-11-12
DK1663287T3 (da) 2009-11-09
TWI342782B (en) 2011-06-01
BRPI0414062B1 (pt) 2019-06-25
ZA200601550B (en) 2007-05-30

Similar Documents

Publication Publication Date Title
MA28032A1 (fr) Utilisation de cyclosporines modifiees pour le traitement de troubles lies au vhc
MA29757B1 (fr) Peptides macrocycliques en tant qu'inhibiteurs de la protease ns3 du vhc
MA30893B1 (fr) Inhibiteurs de la protease ns3 du vhc
MA30198B1 (fr) Inhibiteurs de la protease ns3 du vhc
BR0008688A (pt) Antagonistas de il-18 recombinantes utilizáveis no tratamento de distúrbios mediados por il-18
EP1390029A4 (fr) Phenylindoles pour le traitement de l'infection par le vih
EP1673078A4 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
BR0114390A (pt) éteres de 7-desmetilrapamicina
EP1646614A4 (fr) Compositions ophtalmiques destinees au traitement d'hypertension oculaire
MA28950B1 (fr) Utilisation de cyclosporine dans le traitement d'infections a hepatite c et composition pharmaceutique contenant ladite cyclosporine
EP1838321A4 (fr) Antagonistes de cxcr4 pour le traitement de l'infection due au vih
MA26221A1 (fr) Nouveaux preconcentres de microemulsion d'analogue de la cyclosporine.
TNSN07066A1 (fr) Inhibiteurs de l'arn-polymerase, dependant d'arn, du virus de l'hepatite c, et compositions et traitements les utilisant
EP1641423A4 (fr) Antagonistes du recepteur du cgrp de
WO2002064096A3 (fr) Procedes d'utilisation d'agents antiviraux a base de pyrimidine
MA30250B1 (fr) Vaccins destines a lutter contre une infection a chlamydia
RU2012120343A (ru) Морфогенные белки кости (bmp), рецепторы вмр и связывающие вмр белки и их применение для диагностики и лечения глаукомы
MA31666B1 (fr) Cyclic peptide cxcr4 antagonists
ATE296108T1 (de) Cyanovirin konjugate, matrix-verankertes cyanovirin und anti-cyanovirin antikörper, und verwandte zusammensetzungen und anwendungen
EP1753777A4 (fr) METHODES ET COMPOSITIONS POUR LE TRAITEMENT ET LA PREVENTION D'UNE INFECTION PAR LE VIH AU MOYEN DE TRIM5a
ATE339968T1 (de) Verwendung von mglur5 antagonists zur herstellung von medikamenten zur behandlung von empfindlichen x syndrome, autismus und geistiger zurückgebliebenheit
MA28038A1 (fr) Thienopyrazoles
MA30865B1 (fr) Utilisation de cyclosporines modifiees
EP1664011A4 (fr) Compositions ophtalmiques pour le traitement de l'hypertension oculaire
EP2322206A3 (fr) Nétrine 1 mutée, ses fragments et leur utilisation comme médicaments